Compare UK & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UK | CNSP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | China | United States |
| Employees | 127 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.8M |
| IPO Year | N/A | 2019 |
| Metric | UK | CNSP |
|---|---|---|
| Price | $0.51 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 87.9K | 17.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.73 |
| 52 Week High | $1.21 | $10.59 |
| Indicator | UK | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 23.35 |
| Support Level | N/A | $0.77 |
| Resistance Level | $1.17 | $8.89 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 37.70 | 7.75 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.